Cyclic peptidomimetic urokinase receptor antagonists

Details Cyclic peptidomimetic urokinase receptor antagonists Cyclic peptidomimetic urokinase receptor antagonists

2006-05-16

2006-05-16

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S011400

Reexamination Certificate

active

07045504

ABSTRACT:
The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.

REFERENCES:
patent: WO 97 12905 (1997-04-01), None
patent: WO 98 21230 (1998-05-01), None
patent: WO 98 46632 (1998-10-01), None
Sato S, et al, “High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread,” FEBS Lett Sep. 25, 2002:528(1-3):212-6.
Magdolen V et al.: Systematic Mutational Analysis of the Receptor-Binding Region of the Human Urokinase-Type Plasminogen Activator European Journal of Biochemistry, DE, Berlin, vol. 237, 1996, pp. 743-751.
Sato et al., “High-affnity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread”, FEBS Letters 528 (2002), 212-216.

Affiliated with

Also associated with

Rating

Cyclic peptidomimetic urokinase receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptidomimetic urokinase receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptidomimetic urokinase receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3649393